Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2022 | RTX-240: allogeneic RBCs drive expansion & trafficking of CD8+ T-cells & NK cells into the TME

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from a Phase I study evaluating RTX-240, an allogeneic cellular therapy genetically engineered to express high copy numbers of trimeric 4-1BBL and IL-15/IL-15Rα fusion proteins on the red blood cell (RBC) surface membrane in order to activate and expand CD8+ memory T-cells and NK cells. RTX-240 is well tolerated at all tested doses and leads to activation, expansion, and trafficking of memory CD8+ T cells and NK cells into the tumor microenvironment (TME). This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.